TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-17

Archived explainer. For the current picture see today's ERAS page.

Why Is ERASCA INC (ERAS) Stock Down Today?

By the Top Tier Newswire AI Desk · November 17, 2026 at 10:32 AM ET · reviewed against 4 wire stories

ERASCA INC (ERAS) is down -6.49% in the latest session. Our newswire has captured 4 stories on ERAS across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Erasca (ERAS) shares fell 6.49% to $14.13 on Monday. The primary driver for the decline appears to be a pullback from recent highs, despite fresh initiation coverage and an upcoming investor event.

What Happened

Leerink initiated coverage on Erasca with an Outperform rating, a move that typically signals institutional confidence in the company's clinical trajectory. Concurrently, the company announced it will host a virtual investor event on November 20, 2026, to highlight clinical momentum across its RAS-targeting franchise. This event follows the release of third-quarter 2026 financial results and business updates. The stock had recently printed a fresh 52-week high, setting the stage for potential profit-taking. Additionally, background context includes the start of a combination clinical trial with Tango Therapeutics and ongoing patent infringement allegations regarding ERAS-0015.

What The Data Shows

The intraday session showed significant volatility, opening at $15.15 and hitting a session high of $15.84 at 9:05 AM ET. The stock then slid to a session low of $14.13 at 10:30 AM ET, closing near that low at $14.19. Volume was 1.6 million shares, which is 0.3 times the three-month daily average, indicating lighter participation than usual. Fundamentals show a market cap of $5.5 billion with the company remaining unprofitable, posting a trailing twelve-month EPS of -0.99. The stock has a beta of 0.65 and a 52-week range of $2.50 to $24.28. Over the last eight sessions, the stock moved down 5.0% from $14.78 to $14.04. The 52-week tape recorded one fresh high and 20 fresh lows on November 17, 2026.

What To Watch

Investors should monitor the virtual investor event scheduled for November 20, 2026, where Erasca plans to detail its clinical progress. The upcoming date provides a near-term catalyst for the stock, which has seen improving sentiment trends over the last seven days.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

ERAS by the numbers

Last: $14.13Session: -6.49%7 sessions: -5.01%Coverage: 4 stories / 3 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $5.5B52w: $2.50 to $24.28
ERAS · Nov 17 session (5-min) · -7.41% vs prior close · updated 8:46 PM ET
$13.47$14.72$15.97prev close $15.11$13.998:00 AM10:55 AM1:50 PM4:45 PM7:40 PM8:00 AM · $15.358:15 AM · $15.598:20 AM · $15.508:30 AM · $15.508:45 AM · $15.619:05 AM · $15.849:25 AM · $15.379:30 AM · $15.209:35 AM · $15.329:40 AM · $15.289:45 AM · $15.159:50 AM · $14.899:55 AM · $14.9610:00 AM · $14.9010:05 AM · $14.6810:10 AM · $14.5010:15 AM · $14.3810:20 AM · $14.4710:25 AM · $14.2910:30 AM · $14.4010:35 AM · $14.4310:40 AM · $14.3010:45 AM · $14.2410:50 AM · $14.1710:55 AM · $14.3511:00 AM · $14.2911:05 AM · $14.4211:10 AM · $14.2911:15 AM · $14.3511:20 AM · $14.2111:25 AM · $14.2511:30 AM · $14.3111:35 AM · $14.3011:40 AM · $14.3411:45 AM · $14.3411:50 AM · $14.3211:55 AM · $14.5312:00 PM · $14.4312:05 PM · $14.4712:10 PM · $14.4912:15 PM · $14.5712:20 PM · $14.5312:25 PM · $14.4712:30 PM · $14.5012:35 PM · $14.3512:40 PM · $14.3912:45 PM · $14.3912:50 PM · $14.3712:55 PM · $14.341:00 PM · $14.371:05 PM · $14.451:10 PM · $14.421:15 PM · $14.421:20 PM · $14.461:25 PM · $14.471:30 PM · $14.491:35 PM · $14.461:40 PM · $14.411:45 PM · $14.421:50 PM · $14.351:55 PM · $14.222:00 PM · $14.222:05 PM · $14.292:10 PM · $14.322:15 PM · $14.162:20 PM · $14.122:25 PM · $14.112:30 PM · $13.972:35 PM · $13.982:40 PM · $13.952:45 PM · $13.932:50 PM · $13.902:55 PM · $13.873:00 PM · $13.833:05 PM · $13.863:10 PM · $13.873:15 PM · $13.823:20 PM · $13.943:25 PM · $13.943:30 PM · $13.873:35 PM · $13.743:40 PM · $13.783:45 PM · $13.853:50 PM · $13.683:55 PM · $13.904:00 PM · $13.894:10 PM · $13.604:20 PM · $13.914:25 PM · $13.994:55 PM · $13.896:50 PM · $14.107:05 PM · $14.317:35 PM · $14.307:40 PM · $13.99
AI sentiment, last 36h · averaged over 4 stories · 61/100 bullish
AI sentiment 61/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishGlobeNewswire · sentiment 58 · Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting FranchiseGlobeNewswire · 58Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targe…StockTitan · sentiment 58 · Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting FranchiseStockTitan · 58Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targe…The Fly · sentiment 63 · Erasca initiated with an Outperform at LeerinkThe Fly · 63Erasca initiated with an Outperform at LeerinkThe Fly · sentiment 64 · Leerink bullish on Erasca, initiates with an OutperformThe Fly · 64Leerink bullish on Erasca, initiates with an Outperform
3d agoThe FlyBULLISH 64Analyst

Leerink bullish on Erasca, initiates with an Outperform

3d agoThe FlyBULLISH 63Analyst

Erasca initiated with an Outperform at Leerink

4d agoGlobeNewswireBULLISH 58Product/PR

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...

4d agoStockTitanBULLISH 58Product/PR

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on ERAS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier ERAS move explainers: 2026-11-18 · 2026-11-17 · 2026-11-13 · 2026-10-16 · 2026-09-23 · 2026-09-10 · 2026-09-02 · 2026-08-27 · 2026-08-26